A recent pilot study reported in the June issue of The Journal of Nuclear Medicine found that sodium fluoride (Na-F-18) positron emission tomography/computed tomography (NaF-PET/CT) accurately detects ...

Prostate-specific membrane antigen (PSMA)-PET/CT imaging identified metastatic prostate cancer in almost half of high-risk cases missed by conventional imaging, a retrospective analysis showed.

Evaluation of the impact on overall survival curves of patients with metastatic castration-sensitive prostate cancer staged with PET-PSMA and classified according to current prognostic criteria by ...

PSMA-PET has an important role in the accurate staging of recurrent prostate cancer. Prostate-specific membrane antigen-positron emission tomography (PSMA-PET) frequently detects metastatic disease ...

Researchers in Denmark conducted a prospective single-centre study including 160 patients with newly diagnosed high-risk prostate cancer between 2021 and 2024. All the participants first underwent an ...

A new study led by researchers at the UCLA Health Jonsson Comprehensive Cancer Center has found that many cases of high-risk nonmetastatic hormone-sensitive prostate cancer may be more advanced than ...

Prostate-specific membrane antigen–positron emission tomography (PSMA-PET) detected metastatic disease in 46% of patients with high-risk prostate cancer previously classified as nonmetastatic by ...

Liv Hospital integrates PET/CT diagnostics, radionuclide therapies and a multidisciplinary council to create individualized treatment plans for complex cancer and cardiac cases.

National guidelines on prostate cancer screening with the PSA test are set by the US Preventive Services Task Force. Marc B. Garnick, the Gorman Brothers Professor of Medicine at Harvard Medical ...